Disclosed is the use of a herbal composition comprising a therapeutically effective amount of an extract of Piper betle leaves as an active ingredient either alone or with at least one pharmaceutically acceptable excipient, for the manufacture of a medicament for the treatment of imatinib-resistant chronic myeloid leukemia.